Notice of Results

RNS Number : 6423P
Venture Life Group PLC
04 September 2017
 

 

Venture Life Group plc

("Venture Life" or the "Company")

 

Notice of Results

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, will announce its half year results for the six months ended 30 June 2017 on 21 September 2017.

 

A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Thursday 21 September 2017.

 

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email venturelife@walbrookpr.com.

 

 For further information please contact:

 

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

 

Adrian Crockett, Chief Financial Officer   

 

 

 

 

 

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

 

Bob Pountney / John Howes (Corporate Broking) 

 

 

 

 

 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner

 

 

 

 

 

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy / Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

 

 

         

 

 

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOREFLFBDKFFBBL
UK 100

Latest directors dealings